Logo

Merck Reports the US FDA's Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough

Share this

Merck Reports the US FDA's Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough

Shots:

  • The NDA submission is based on two P-III studies (COUGH-1 & -2) involves assessing gefapixant (45/15mg- bid) vs PBO in 2-044 patients with RCC & UCC
  • In both the studies- gefapixant resulted in the reduction of in 24hrs.-cough frequency @12 & 24wks respectively. Data were presented at ERS 2020
  • Gefapixant is a selective P2X3 receptor antagonist for the potential treatment of refractory or unexplained chronic cough. The anticipated PDUFA date is Dec 21- 2021

 ­ Ref: Businesswire | Image: Merck 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions